...
首页> 外文期刊>Scientific reports. >Efficacy of covered and bare stent in TIPS for cirrhotic portal hypertension: A single-center randomized trial
【24h】

Efficacy of covered and bare stent in TIPS for cirrhotic portal hypertension: A single-center randomized trial

机译:TIPS覆膜支架和裸支架治疗肝硬化门脉高压的疗效:单中心随机试验

获取原文
           

摘要

We conducted a single-center randomized trial to compare the efficacy of 8 mm Fluency covered stent and bare stent in transjugular intrahepatic portosystemic shunt (TIPS) for cirrhotic portal hypertension. From January 2006 to December 2010, the covered (experimental group) or bare stent (control group) was used in 131 and 127 patients, respectively. The recurrence rates of gastrointestinal bleeding (18.3% vs. 33.9%, P = 0.004) and refractory hydrothorax/ascites (6.9% vs. 16.5%, P = 0.019) in the experimental group were significantly lower than those in the control group. The cumulative restenosis rates in 1, 2, 3, 4, and 5-years in the experimental group (6.9%, 11.5%, 19.1%, 26.0%, and 35.9%, respectively) were significantly lower (P 0.001) than those in the control group (27.6%, 37.0%, 49.6%, 59.8%, 74.8%, respectively). Importantly, the 4 and 5-year survival rates in the experimental group (83.2% and 76.3%, respectively) were significantly higher (P = 0.001 and 0.02) than those in the control group (71.7% and 62.2%, respectively). The rate of secondary interventional therapy in the experimental group was significantly lower than that in the control group (20.6% vs. 49.6%; P 0.001). Therefore, Fluency covered stent has advantages over the bare stent in terms of reducing the restenosis, recurrence, and secondary interventional therapy, whereas improving the long-term survival for post-TIPS patients.
机译:我们进行了一项单中心随机试验,比较了8 mm Fluency覆膜支架和裸支架在经颈静脉肝内门体分流术(TIPS)中治疗肝硬化门脉高压的疗效。从2006年1月至2010年12月,分别对131例和127例患者使用了覆盖(实验组)或裸支架(对照组)。实验组胃肠道出血的复发率(18.3%vs. 33.9%,P = 0.004)和难治性胸水/腹水(6.9%vs. 16.5%,P = 0.019)显着低于对照组。实验组在1年,2年,3年,4年和5年的累计再狭窄率(分别为6.9%,11.5%,19.1%,26.0%和35.9%)显着低于那些(P <0.001)对照组(分别为27.6%,37.0%,49.6%,59.8%,74.8%)。重要的是,实验组的4年和5年生存率(分别为83.2%和76.3%)显着高于对照组(分别为71.7%和62.2%)(P = 0.001和0.02)。实验组的二次介入治疗率显着低于对照组(20.6%比49.6%; P <0.001)。因此,在减少再狭窄,复发和二次介入治疗方面,流利性覆膜支架比裸支架具有优势,而提高了TIPS后患者的长期生存率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号